Drugs / IDE849
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07174583 | Oct 2025 → Jul 2029 expected | small cell lung carcinoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDE849 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07174583 ↗ |
| Route | Intravenous | “IV administration” NCT07174583 ↗ |
| Target | DLL3 | “an anti-DLL3 antibody-drug conjugate” NCT07174583 ↗ |